| Abstract |
Abstract: Objective: To explore the value of the combination of esmcitalopram and cognitive behavior in depression patients. Methods: 92 patients with depression were selected (January 2019 to December 2020), and divided into control group (n=46, esmcitalopram) and observation group (n=46, cognitive behavior therapy based on the control group). The clinical efficacy, adverse response score, recurrence rate and clinical indicators were statistically analyzed. Results: (1) the clinical effect: the observation group (95.65%) was higher than the control group (78.26%), and the comparison between the groups was p < 0.05. (2) Recurrence rate: the recurrence rate of observation group (4.35% in 1 year and 8.69% in 2 years) was lower than that of the control group, and the comparison between the groups was p < 0.05. (3) Adverse reactions score: there was no difference between the observation group and the control group in the first week, the difference was p > 0.05, the score of the sixth week (4.31 ± 1.06) was lower than that of the control group (7.42 ± 0.52), and the comparison between the groups was p < 0.05. (4) Clinical indicators: the depression, anxiety and S100B in the observation group were lower than that of the control group, and the social function, cognitive function and BDNF were higher than that of the control group, and the comparison between the groups was p < 0.05. Conclusion: the effect of esmcitalopram combined with cognitive behavior in depression treatment is accurate, it can improve the depression state and cognitive function, promote the recovery of social function, ensure the safety and effectiveness of treatment, which is worth reference.
|